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Combination of Dacarbazine and Dimethylfumarate
Efficiently Reduces Melanoma Lymph Node
Metastasis
Teresa Valero1,2, Silvia Steele1, Karin Neumu¨ller1, Andreas Bracher1, Heide Niederleithner1,
Hubert Pehamberger2, Peter Petzelbauer1,2 and Robert Loewe1,2
Dimethylfumarate (DMF) has been shown to reduce melanoma growth and metastasis in animal models.
We addressed the question of whether DMF is as effective in its antitumor activity as the US Food and Drug
Administration–approved alkylating agent dacarbazine (DTIC). We also tested the possibility of an improved
antitumoral effect when both therapeutics were used together. Using our severe combined immunodeficiency
(SCID) mouse model, in which xenografted human melanoma cells metastasize from primary skin sites to
sentinel nodes, we show that these treatments, alone or in combination, reduce tumor growth at primary sites.
Our main finding was that metastasis to sentinel nodes is significantly delayed only in mice treated with a
combination of DTIC and DMF. Subsequent experiments were able to show that a combination of DTIC/DMF
significantly reduced lymph vessel density in primary tumors as examined by real-time PCR and
immunohistochemistry. In addition, DTIC/DMF treatment significantly impaired melanoma cell migration
in vitro. In vivo, DTIC/DMF therapy significantly reduced mRNA expression and protein concentration of the
promigratory chemokines CXCL2 and CXCL11. In addition, our data suggest that this xenotransplantation model
is suitable for preclinical testing of various combinations of antimelanoma agents.
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INTRODUCTION
Metastatic melanoma has a poor prognosis. The mean
survival time from first appearance of distant metastases is
6–9 months, and in most patients, distant metastases are
directly responsible for cancer-related death in advanced-
stage melanoma. Melanoma can metastasize via three routes:
(i) continuous (per continuitatem), with tumor growth
extending from the primary tumor; (ii) lymphogenic, into
regional (sentinel) lymph nodes; and (iii) hematogenic, into
distant organs, including the lungs and brain (Balch et al.,
2001). Usually, lymphogenic metastasis into regional lymph
nodes (clinical stage III) precedes hematogenic metastases
in distant organs (clinical stage IV; Balch et al., 2001). Of the
several mechanisms that account for the development of
metastases, induction of tumor cell proliferation, inhibition of
apoptosis, and mobilization and invasion of tumor cells, as
well as tumor vessel formation, are the most important
(Hanahan and Weinberg, 2000; Steeg, 2006).
Many efforts have been made to find a therapy to improve
the prognosis for metastatic melanoma, but for more than
two decades the only Food and Drug Administration–
approved systemic therapeutic options for stage IV melanoma
have been the cytotoxic agent dacarbazine (DTIC), IL-2,
and hydroxyurea (Tsao et al., 2004; Garbe and Eigentler,
2007; Mansfield and Markovic, 2009). Of the three, DTIC
is by far the most often used drug because of its better
effect/side effect ratio. Interestingly, although it has been in
therapeutic use for more than 30 years, DTIC’s mechanism
of action has not yet been fully elucidated (Eggermont
and Kirkwood, 2004). Possible mechanisms by which
DTIC exerts it effect are (i) alkylation of nucleic acids
(Gerulath and Loo, 1972), (ii) inhibition of purine base
incorporation during DNA synthesis (Hayward and Parsons,
1984), and (iii) interaction with protein sulfhydryl radicals
(Saunders and Schultz, 1972). In summary, DTIC exhibits a
cytotoxic effect and induces tumor cell apoptosis (Soengas
and Lowe, 2003). The overall response rate of DTIC is only
15–20%, but even in patients with clinical responses these
observed responses are temporary because the drug usually
induces chemoresistance after a few cycles of chemotherapy.
Altogether, DTIC prolongs only the disease-free interval,
not median overall survival (Khan et al., 2006); therefore
new therapeutic options for metastatic melanoma are
urgently needed.
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Dimethylfumarate (DMF) is a fumaric acid ester used
successfully in the treatment of psoriasis (Mrowietz et al.,
2007). We have previously shown that DMF reduces
melanoma growth and metastasis in severe combined
immunodeficiency (SCID) mouse xenotransplantation models
through its antiproliferative and proapoptotic effects (Loewe
et al., 2006). Previous studies were able to identify inhibition
of the NF-kB signaling pathway in endothelial cells and
dermal fibroblasts as a possible explanation for the observed
therapeutic effects (Loewe et al., 2001, 2002; Vandermeeren
et al., 2001). Other studies have extended these findings by
identifying similar DMF effects in other cell types (Schilling
et al., 2006; Gesser et al., 2007; Meili-Butz et al., 2008).
DMF is also able to interfere with the intracellular redox
system by depleting glutathione and consequently inducing
heme oxygenase 1 (Lehmann et al., 2007; Schmidt et al.,
2007). The NF-kB signaling pathway is critical in cancer
development and progression and is activated constitutively
in various types of tumors, including melanoma (Yang and
Richmond, 2001). Therefore, Rel transcription factors and the
signaling pathways that regulate their activity are promising
targets for cancer prevention and therapy (Karin, 2006; Yang
et al., 2006).
By using the M24met human melanoma xenotransplanta-
tion model, we sought to evaluate the therapeutic potential of
DMF in comparison or in combination with the established
standard chemotherapeutic DTIC. We therefore have ana-
lyzed treatment effects on primary tumor growth and lymph
node metastasis in this spontaneously metastasizing mouse
melanoma model. We can conclude from our data that a
combination therapy of DTIC/DMF is superior to all other
treatment modalities for reduction of lymph node metastasis.
We were also able to show that this model is a convenient
and valuable tool for testing therapeutic strategies for
metastatic melanoma.
RESULTS
Growth of primary melanoma
A first set of experiments evaluated the therapeutic effects of
different treatment strategies (DMF, DTIC, DTIC/DMF) on the
growth of primary human melanomas in SCID mice. In our
model using human M24met melanoma cells injected
intradermally into mice, treatment was initiated when tumors
were clinically apparent (palpable tumors, approximately
2mm in diameter). Treatment with DMF or DTIC alone or in
combination (DTIC/DMF) reduced tumor volumes compared
with tumors grown in control animals, but the extent of the
reduction was not statistically significant (Figure 1).
Melanoma metastases in sentinel lymph nodes
After excision of primary tumors, mice were treated for
another 10 days. Lymph nodes were then excised, and lymph
node metastases were analyzed by immunohistochemistry
using an antibody against human vimentin. This antibody
shows no cross-reactivity with mouse vimentin (Loewe et al.,
2006). The ipsilateral axillary lymph node was invariably
the first lymph node (the so-called sentinel lymph node)
that showed melanoma metastases in our spontaneously
metastasizing model. Sentinel lymph nodes within all treat-
ment groups (n¼ 24, total yield 100%) were examined for
melanoma metastases (Figure 2). Mean sentinel lymph node
volume was reduced significantly in DTIC/DMF-treated
animals (Po0.05). Reduction by other treatment modalities
was not significant.
Effects of DTIC and DMF on tumor blood and lymph vessels
To identify the distribution of blood and lymph vessels in
primary tumors, we carried out double staining of the
panendothelial vessel marker CD31 and the lymphatic vessel
marker Lyve-1 (see Materials and Methods). As shown in
Figure 3a, immunofluorescence on tumor tissue cryosections
shows that CD31þ /Lyve-1þ lymphatic vessels outnumber
CD31þ /Lyve-1 blood vessels in the primary melanomas of
our xenotransplantation model.
By analyzing the mRNA expression of the panendothelial
marker CD31 by reverse transcriptase (RT)–PCR, no treatment
condition (DMF, DTIC, DTIC/DMF) significantly altered
CD31 mRNA expression (Figure 3b). Expression levels of
CD144 and Prox-1 mRNAs were also analyzed. CD144 (VE-
cadherin) is a junctional protein predominantly expressed in
blood endothelial cells as well as, to a lesser extent, on
lymphatic endothelial cells, and Prox-1 is a highly specific
marker for lymphatic endothelial cells. Both CD144 and
Prox-1 mRNA expression levels were reduced by 40% after
DTIC/DMF treatment; nevertheless, the reduction in mRNA
expression remained statistically insignificant (CD144:
P¼0.11; Prox-1: P¼ 0.083). Treatment with DMF or DTIC
had no influence on CD144 mRNA expression, whereas both
DMF and DTIC single treatments were able to reduce Prox-1
mRNA. However, this reduction was less distinct than that
achieved by DTIC/DMF treatment (Figure 3b).
Because Prox-1 mRNA expression was most effectively
reduced after DTIC/DMF treatment, we next evaluated
possible changes in lymph vessel density in primary tumors.
Using immunohistochemistry with antibodies against mouse
podoplanin, Lyve-1, and Prox-1, we identified changes in the
amount of antibody-stained lymphatic vessels (podoplanin
M24met
1,600
1,400
1,200
1,000
800
600
400
200
0T
u
m
o
r 
vo
lu
m
e 
in
 m
m
3
0 2 4 6 8 10
Days
Control
DMF
DTIC
DTIC+DMF
Figure 1. Reduction of primary tumor growth in a severe combined
immunodeficiency (SCID) mouse melanoma xenotransplantation model.
Growth of human M24met melanoma cells in SCID mice before (day 1) and
during treatment was measured daily. Tumor cell inoculation, treatment
protocol, and tumor volume calculation were as described in Materials and
Methods. n¼6 animals per group; volumes are shown as mean±SEM,
Po0.05.
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and Lyve-1) as well as in the amount of Prox-1-stained nuclei
of lymphatic endothelial cells (Figure 3c). Lyve-1 and Prox-1
immunostaining showed significant reduction of Lyve-1 and
Prox-1 positivity in DTIC/DMF-treated primary tumors (Figure
3c) when compared with control tumors or with tumors
treated with DMF or DTIC alone. Staining with antibodies
against mouse podoplanin did not reveal significant differ-
ences in the amount of positive staining among the different
treatment groups (Figure 3c).
Effects of DTIC and DMF on cell motility and stromal
chemokine expression
Tumor metastasis strongly depends on the ability of tumor
cells to migrate to and into the vasculature upon appropriate
chemotactic signals. To test whether various treatment
conditions also influence tumor cell motility, we performed
a wounding assay in vitro. In this assay, a confluent
monolayer of human M24met melanoma cells was disrupted,
and the amount of regrowth into this area was measured after
the indicated time points (see Materials and Methods).
Treatment with DTIC/DMF led to a significant reduction in
tumor cell migration; after 72 hours less than 50% of the
wounded area was recovered by tumor cells. This result
differed from results obtained in experiments performed with
DTIC or DMF alone. In both treatment groups, the wounded
area was recovered with cells after 72 hours, which was also
true for the untreated control cells (Figure 4a).
To analyze whether changes in chemotactic gradients may
lead to altered migration of melanoma cells, we analyzed the
expression of promigratory chemokines in the stroma of
primary tumors in our mouse xenotransplantation model.
DTIC/DMF treatment significantly reduced mRNA expression
of chemokines CXCL2 and CXCL11, as well as of the
promigratory cytokine tumor necrosis factor-a (TNF-a; data
not shown), as analyzed by RT-PCR. Treatment with DTIC or
DMF alone showed a reduction in mRNA expression of
CXCL2, CXCL11, and TNF-a when compared with untreated
control mice, but these therapies were less effective than a
combination therapy of DTIC/DMF (Figure 4b).
Protein levels of these factors were analyzed by ELISA in
the lysates of primary tumor samples taken from our M24met
melanoma model (Figure 4c). Murine CXCL2 protein levels
were significantly reduced with DTIC alone or with a DTIC/
DMF combination. In this assay, DTIC most efficiently
reduced CXCL2 protein levels. Reduction in CXCL11 protein
levels was greater with DMF/DTIC treatment than with DMF
or DTIC alone as well as in control animals (Figure 4c).
DISCUSSION
Several mechanisms are responsible for the development of
metastases: (i) increased tumor growth, (ii) inhibition of
apoptosis, (iii) neoangiogenesis of blood and lymph vessels,
(iv) direct interactions with the surrounding stroma, and
(v) increased concentrations of chemoattractants. DTIC is
antiproliferative (Alley et al., 1984) and proapoptotic
(Soengas and Lowe, 2003) in vitro and in vivo. We have
previously shown that DMF is also antiproliferative and
proapoptotic and that it has an inhibitory effect on the NF-kB
signaling pathway (Loewe et al., 2006). We postulated that
these two substances might have an additive antiproliferative
and proapoptotic effect. In addition, given that inhibition of
NF-kB is known to reduce chemoresistance, we speculated
that DMF might enhance and/or prolong the therapeutic
effect of DTIC (Aggarwal, 2004). Interestingly, in our
experiments we were not able to identify additive effects on
tumor cell proliferation or on apoptosis. The number of
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Figure 2. A combination of dacarbazine/dimethylfumarate (DTIC/DMF) is most effective in the reduction of lymph node metastases. Lymph nodes of
M24met-bearing mice were collected after 18 days of treatment and stained immunohistochemically with an antihuman vimentin antibody (see Materials and
Methods). Lymph nodes were grouped into macrometastases (macroscopically enlarged lymph nodes), micrometastases (normal-sized lymph nodes with
melanoma cell infiltration stained red), and tumor-free lymph nodes. Bars¼1mm (left) and 500 mm (center and right). Volumes of lymph node metastases in
ipsilateral axillary lymph nodes (sentinel lymph nodes) were assessed by measuring vimentin-positive areas (red). n¼ 6 animals per group; volumes were
expressed as mean±SEM, *Po0.05.
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proliferating tumor cells as assessed with Ki-67 immuno-
histochemistry did not differ among various treatment groups
(data not shown). Regarding effects on tumor cell apoptosis,
DMF-, DTIC-, and DTIC/DMF-treated tumors did not show
relevant differences in the extent of tumor cell apoptosis to
sufficiently explain the observed differences in lymph node
metastasis (data not shown). In addition, the ratio of necrotic
to viable tumor tissue did not reveal any differences between
primary tumors of treated animals when compared with
control tumors (data not shown). Therefore, an increased
inhibition of proliferation or induction of apoptosis cannot
solely account for the observed significant differences in
lymph node metastases in the DTIC/DMF group in compar-
ison to the other treatment groups.
Neoangiogenesis of blood and lymph vessels in and
around growing primary tumors is an important contributor
to the development of lymph node metastases (Carmeliet
and Jain, 2000). In melanoma, a direct correlation
between increased tumor lymphangiogenesis and increased
lymphatic metastasis has been established in animal models
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Figure 3. Dacarbazine/dimethylfumarate (DTIC/DMF) treatment significantly reduces lymphatic vessel density in primary tumors. (a) M24met primary
tumor cryosections were stained by immunofluorescence with the panendothelial vessel marker CD31 (red) and the lymphatic vessel marker Lyve-1 (green).
Lymphatic vessels were double positive (**), blood vessels were only CD31þ (*). Cell nuclei were counterstained with 40,6-diamidino-2-phenylindole
dihydrochloride (blue; see Materials and Methods). Bar¼ 200mm. (b) Real-time PCR analysis of mRNA expression of mouse blood and lymphatic vessel markers
CD31, CD144, and Prox-1, measured on tissue samples from mouse xenotransplantation experiments. (c) Immunohistochemistry of primary tumors with
antibodies against mouse podoplanin, Lyve-1, and Prox-1. Representative photomicrographs of control tumors stained with indicated antibodies are shown
(see Materials and Methods; vessel lumina in Prox-1-stained image are marked with red asterisk; bar¼50 mm). Positive pixel count in percentage of total
pixel number is given for stainings against podoplanin and Lyve-1. Amount of Prox-1 positivity is given by number of positive nuclei per high-power field (HPF).
Statistical significance was set at Po0.05 (*).
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(He et al., 2004) and in clinical studies on melanoma patients
(Dadras et al., 2005; Massi et al., 2006). Conversely, as recent
studies have already elucidated, reduced vessel density may
account for inhibited primary tumor growth as well as
impaired metastasis (Liang et al., 2006). Immunohistochem-
istry revealed that lymphatic vessels outnumber blood vessels
in and around primary tumors in our xenotransplantation
model. In our experiments, DTIC/DMF treatment reduced
lymph vessel density in primary tumors, as seen by reduction
of mRNA expression of the lymphatic marker Prox-1 as well
as by a significant reduction of Lyve-1þ and Prox-1þ
vessels as assessed by immunohistochemistry. DTIC/DMF
treatment was significantly more effective than therapy with
DMF or DTIC alone. The fact that stromal fibroblasts also
stained positive for podoplanin might explain why no clear
differences were observed in the podoplanin staining of
treated and untreated primary tumors.
As mentioned above, various chemoattractants are also
crucial in the successful establishment of distant metastases.
These substances are able to mobilize tumor cells, increase
tumor cell motility, and target and guide tumor cells into
specific host organs (Hanahan and Weinberg, 2000; Cabioglu
et al., 2005; Steeg, 2006; Lin and Karin, 2007; Shields et al.,
2007). We tested the regulation of chemo- and cytokines
known to influence tumor cell migration. Treatment with
DTIC/DMF significantly and most potently reduced mRNA
expression of several such factors, such as TNF-a and the
chemokines CXCL11 and CXCL2 in vivo. Interestingly,
expression of all of these factors is under the transcriptional
control of NF-kB (Loewe et al., 2001; Chang et al., 2009;
Tang et al., 2009), which is known to be inhibited by DMF
(Loewe et al., 2001). Chemokines CXCL11 and CXCL2
exhibit their chemotactic and motility-increasing effects on
human tumor cells through their cognate receptors CXCR3
and CXCR2, respectively (Kawada et al., 2004; Proost et al.,
2007; Richmond et al., 2009). M24met melanoma cells
express both receptors, CXCR3 and CXCR2, as shown by RT-
PCR and immunohistochemistry (data not shown). By
analyzing protein levels in tumor lysates, we found a
significant reduction of CXCL2 and CXCL11 protein levels
in the tumor stroma, thus further confirming our mRNA
expression data. CXCL11 has also been described as
exhibiting angiostatic potential (Richmond et al., 2009).
Nevertheless, in our experimental model, reduction of
CXCL11 mRNA expression did not lead to increased vessel
density or increased mRNA expression of vascular markers
(see Figure 3). The proinflammatory cytokine TNF-a also
exhibits potent promigratory effects on human melanoma
cells; a significant reduction in TNF-a mRNA expression has
been shown to reduce tumor cell motility (Katerinaki et al.,
2003; Zhu et al., 2004). We were able to show reduced
mRNA expression of murine TNF-a, but in our assay,
unfortunately, we were not able to detect TNF-a protein
reliably in tumor lysates. This may be due to protein
instability.
In line with the observed reduction of promigratory
chemokines in vivo is the finding that DTIC/DMF treatment
was most potent among all treatments tested in inhibiting
migration of human M24met cells in vitro. Taken together,
these data favor the possibility that DTIC/DMF treatment
inhibits melanoma lymph node metastasis by reducing lymph
vessel density in primary tumors as well as influencing
migration of tumor cells. Because DMF is an approved, well-
tolerated drug that has been in use for the treatment of
psoriasis for many years, a therapy combining DTIC and DMF
appears to be a reasonable new possibility to broaden
therapeutic options for patients with stage IV melanoma.
MATERIALS AND METHODS
Cell lines, antibodies, and therapeutics
Human melanoma cell lines M24met (kindly provided by RA
Reisfeld; Mueller et al., 1991) and A375 (ATCC cell line, purchased
from LGC Promochem, Wesel, Germany) were cultivated in Iscove’s
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Figure 4. Dacarbazine/dimethylfumarate (DTIC/DMF) treatment inhibits
tumor cell migration and expression of stromal chemokines. (a) In vitro
wounding assay. Confluent monolayers of human M24met melanoma cells
were scratched (see Materials and Methods) and regrowth of cells into the
cell-free area was measured after indicated time intervals. Percentages of
recovered areas are expressed as mean± SEM, *Po0.05. (b) Reverse
transcriptase PCR analysis of mRNA expression of mouse stromal chemokines
CXCL2 and CXCL11. Statistical significance was set at Po0.05 (*). (c)
Quantification of CXCL2 and CXCL11 protein levels in tumor stroma by
ELISA. Protein lysates from primary M24met melanomas grown intradermally
in severe combined immunodeficiency mice and treated with indicated
therapies for 10 days were analyzed (see Materials and Methods). Statistical
significance was set at Po0.05 (*).
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modified Dulbecco’s medium supplemented with 10% fetal calf
serum (Life Technologies, Vienna, Austria), 2mMl1 glutamine (Life
Technologies), and 50 IUml1 penicillin–streptomycin (Life Tech-
nologies). Monoclonal mouse antihuman vimentin antibody (clone
V9) and isotype control antibodies were from Dako Denmark A/S
(Glostrup, Denmark). Rat monoclonal antibody against mouse CD31
(PECAM-1) was purchased from BD Pharmingen (San Jose, CA).
Hamster polyclonal anti-mouse podoplanin, rabbit polyclonal anti-
mouse Lyve-1, and rabbit polyclonal anti-mouse Prox-1 antibodies
were purchased from Acris Antibodies (Hiddenhausen, Germany).
Tetramethylrhodamine isothiocyanate–labeled second-step anti-
bodies were from Jackson ImmunoResearch (West Grove, PA),
Alexa Fluor 488-labeled second-step antibodies were from
Invitrogen (Eugene, OR).
For mouse experiments, DMF (20mg kg1; Sigma, Vienna,
Austria) was suspended in 0.8% methylcellulose and administered
orally daily through gavage (Loewe et al., 2006). DTIC (80mg kg1;
Medac, Wedel, Germany) was given intraperitoneally in cycles of 5
consecutive days per week (Heere-Ress et al., 2005).
For in vitro assays, DMF was solubilized in methanol as a 70mM
stock solution and diluted in Iscove’s modified Dulbecco’s medium
for final concentrations. Stock solutions were stored at 4 1C until
needed and then used within 24 hours. DTIC (stock concentration
10mgml1 distilled water) was light activated for 60minutes before
use and further diluted to the final concentration in Iscove’s modified
Dulbecco’s medium.
SCID mouse xenotransplantation model
Female, pathogen-free, 4- to 6-week-old CB17 SCID (scid/scid) mice
were obtained from Charles River (Sulzfeld, Germany) and housed
as described previously (Loewe et al., 2006). All procedures were
carried out in accordance with the Association for Assessment and
Accreditation of Laboratory Animal Care guidelines and the Guide
for the Care and Use of Laboratory Animals (US Department of
Health and Human Services, National Institutes of Health, publica-
tion no. 86–23). In addition, all experiments were approved by the
ethics committee of the Medical University of Vienna and by the
Austrian government committee on animal experimentation (refer-
ence no. GZ 66.009/33-BrGT/2006). A spontaneously metastasizing
model using human M24met melanoma cells as described pre-
viously was used (Loewe et al., 2006). Briefly, 1 106 of M24met
human melanoma cells were injected intradermally into the right
flank of each animal. When tumors were palpable, treatment was
initiated. Tumors were measured with calipers on a daily basis, and
volumes were calculated as previously described (Loewe et al.,
2006). Primary tumors were excised at volumes of 500–900mm3,
and treatment was continued. Ten days later, animals were killed
and lymph nodes were removed. The tumor tissues were divided.
One part was fixed with 4% paraformaldehyde and embedded in
paraffin; the second was embedded in OCT (Tissue-Tek, Sakura
Finetek Europe, Zoeterwoude, The Netherlands) and snap-frozen for
cryosections and immunofluorescence; and the third was stored in
RNAlater (Ambion, Austin, TX) for mRNA analysis. Lymph nodes
were fixed in 4% paraformaldehyde for immunohistochemistry.
Assessment of lymph node metastases
Formalin-fixed and paraffin-embedded lymph nodes were stained
with hematoxylin and eosin according to standard procedures.
Lymph nodes were grouped into macroscopically enlarged (macro-
metastases) and regular-sized lymph nodes. Macrometastatic lymph
nodes were cut at their largest diameter before processing. For
immunohistochemistry, serial sections were deparaffinized accord-
ing to routine procedures and incubated in citrate buffer (pH 6.0;
Dako Denmark A/S) overnight at 80 1C. Staining with an antibody
against human vimentin (clone V9), which does not cross-react with
mouse vimentin, and an appropriate isotype control was performed
using a DAKO TechMate Horizon automated staining system
according to the manufacturer’s protocol and as described pre-
viously (Loewe et al., 2006). Tumor volumes of lymph node
metastases were calculated from hematoxylin-and-eosin-stained
slides using an AxioCam MRc5 digital camera (Zeiss, Vienna,
Austria) attached to an AH3-RFCA microscope (Olympus, Vienna,
Austria) and AxioVision Rel 4.4 software (Zeiss).
Analysis of blood and lymph vessels
Anti-mouse CD31 and Lyve-1 double staining was performed with
immunofluorescence on 4 mm cryosections, fixed in acetone and air-
dried for 30minutes. After incubation with respective secondary
antibodies, 40,6-diamidino-2-phenylindole dihydrochloride (Sigma,
St Louis, MO) was used for nuclear counterstaining. Sections were
analyzed on a confocal laser scan microscope (LSM 510; Zeiss).
For immunohistochemical staining of murine lymphatic tumor
vessels, formalin-fixed and deparaffinized primary tumor sections
were treated with citrate buffer (pH 6.0) for antigen retrieval by
heating using an autoclave at either 100 1C for 10minutes or 80 1C
overnight. Binding of primary antibodies was detected with a
biotinylated anti-hamster antibody and a streptavidin–biotin–horser-
adish peroxidase complex (for podoplanin antibody detection) or by
using an anti-rabbit horseradish peroxidase UltraVision LP Detection
System (Thermo Scientific, Fremont, CA) for Prox-1 antibody
detection. Finally, counterstaining of both stainings was performed
using Papanicolaou’s hematoxylin solution (Merck, Darmstadt,
Germany). Lyve-1 staining was performed in a DAKO TechMate
Horizon automated staining system following the manufacturer’s
instructions. Quantification of positive-stained tissue areas/positive-
staining nuclei was assessed using ImageScope software (Aperio
Technologies, Vista, CA).
mRNA expression in vivo
RNA was prepared from tissue samples stored in RNAlater using
RNeasy Mini RNA kits (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. RNA was reverse transcribed into first-
strand cDNA using Revert Aid M-MulV Reverse Transcriptase
(Fermentas, Vienna, Austria) and hexamer primers (Roche, Vienna,
Austria) for 90minutes at 42 1C. Real-time PCR was performed
in doublets as previously described (Loewe et al., 2006). The
primer sets used for detection of specific target gene mRNA were
Assays-on-Demand (Applied Biosystems, Vienna, Austria; Table 1).
For normalization, a b-2 microglobulin (b-2m) primer set was
used (Applied Biosystems; Table 1). Reactions were run on an ABI
Prism 7700 Sequence Detector (PerkinElmer, Vienna, Austria), and
data were analyzed with the SDS 1.9.1 software (Applied
Biosystems). Changes in mRNA concentration were determined
by subtracting the Ct (cycle threshold) of the target gene from the
Ct of the housekeeping gene (b-2m) (D¼Ct gene–Ct b-2m). The
mean of D control was subtracted from the D target gene reaction
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(mean D control – D target gene). The difference was calculated
as 2(DDCt).
In vitro wounding assay
Cultured M24met tumor cells (300,000 per well) were plated onto
six-well plates (Costar; Corning, Corning, NY) in 3ml medium and
were allowed to grow until they had formed a compact monolayer.
Using a pipette tip, the cellular monolayer was scratched twice per
well to obtain cell-free lines followed by repeated washing to
remove cellular debris. Cells were then cultivated in medium
containing the indicated concentrations of DMF, DTIC, DTIC/DMF,
or medium alone, which was renewed every 24 hours. A black line
drawn on the undersurface of the well plate was used to identify the
wounded area during re-epithelialization. For documentation,
photographs were taken immediately after wounding and 48 and
72 hours later. The amount of migration was quantified by placing
the measured wound size area at 72 hours in relation to the
respective original wound size using AxioVision Rel 4.4 software.
Mouse chemokine ELISA
Primary tumors grown intradermally in SCID mice and treated with
the indicated conditions were removed, and tumor sections (50mg)
were snap-frozen in liquid nitrogen. Tissue was extracted into 750ml
of lysis buffer containing 50mM Tris-HCl (pH 7.4), 150mM NaCl,
0.5% NP-40, 1mM EDTA, 10 ml ml1 Protease Inhibitor Cocktail
(Sigma, St Louis, MO) by tissue homogenization using Mixer Mill
MM200 (2minutes, 20 per second; Retsch, Haan, Germany) and
centrifugation at 15,000 r.p.m. for 10minutes at 4 1C. Supernatants
were collected and were either used immediately or stored at
80 1C. Mouse CXCL2/CXCL11 DuoSet ELISA was purchased from
R&D Systems (R&D Systems Europe, Abingdon, UK) and the assay
was performed according to the manufacturer’s instructions. Results
were normalized to total protein concentration using a modified
Bradford assay (Bio-Rad Laboratories, Hercules, CA).
Statistical analyses
Statistical comparison was performed with two-sided Student’s t-test.
P-values o0.05 were considered statistically significant. Calcula-
tions were performed with SPSS 16 software (SPSS, Chicago, IL).
Statistical results are presented as mean±standard error of the
mean (SEM).
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